ADT	Androgen deprivation therapy
APOE	Apolipoprotein E
AR	Androgen receptor
AREAS	Areas of epigenetic susceptibility
BCR	Biochemical recurrence
BPH	Benign prostate hyperplasia
CAFs	Cancer-associated fibroblasts
CGA	Comprehensive geriatric assessment
COPD	Chronic obstructive pulmonary disease
DDR	DNA damage response
ECM	Extracellular matrix
EMT	Epithelial-to-mesenchymal transition
EO-PC	Early-onset prostate cancer
ER	Estrogen receptor
GENIE	Genomics Evidence Neoplasia Information Exchange
GSIs	Gamma secretase inhibitors
HR	Homologous recombination
ICIs	Immune checkpoint inhibitors
LO-PC	Late-onset prostate cancer
mCRPC	Metastatic castration-resistant prostate cancer
MDSCs	Myeloid-derived suppressor cells
PARPi	Poly (ADP-ribose) polymerase inhibitor
PC	Prostate cancer
PCSM	Prostate cancer-specific mortality
PFS	Progression-free survival
PRS	Polygenic risk score
PSA	Prostate-specific antigen
ROS	Reactive oxygen species
SASP	Senescence-associated secretory phenotype
SIR	Standardized incidence ratio
TAMs	Tumor-associated macrophages
TMB	Tumor mutational burden
TME	Tumor microenvironment